Araceli Biosciences Inc.

Based in the US, Araceli Biosciences Inc. is a biotechnology company focused on developing advanced AI-driven image acquisition and analysis technologies to enhance therapeutic discovery processes. Araceli Biosciences Inc. specializes in the development of innovative technologies aimed at improving drug discovery through predictive AI-based image analysis.

Founded in 2022 in Tigard, Oregon, US, the company has engaged in one significant deal as of December 2024, raising USD 2. 525 million in SEED funding, which represents the total amount raised to date. The company is led by a team with a background in biotechnology and product development, though specific details about the founder’s previous ventures are not available. Araceli Biosciences specializes in advanced technologies for predictive AI-based image acquisition and analysis, aimed at enhancing the therapeutic discovery process.

Their core product offerings consist of hardware and software solutions designed to facilitate rapid and efficient drug screening, enabling researchers to make informed decisions regarding therapeutic success. By integrating sophisticated artificial intelligence algorithms with user-friendly interfaces, researchers can quickly analyze high-content imaging data. The company primarily targets pharmaceutical and biotechnology firms involved in drug development, along with academic research institutions, marketing its products to clients across North America, Europe, and Asia. Araceli Biosciences generates revenue through a structured B2B model, focusing on partnerships with pharmaceutical companies and research institutions.

The company provides subscription-based access to its advanced software platforms, along with one-time purchases of its imaging hardware. This revenue model ensures recurring income through ongoing software support and updates, with additional transactional agreements for high-volume use of its technology during various drug discovery stages. Pricing plans for flagship products are tailored to accommodate a variety of customer needs, ensuring accessibility for both large pharmaceutical companies and smaller biotech firms. In December 2024, Araceli Biosciences Inc.

raised USD 2. 53 million in SEED funding, which will support the launch of new products designed to enhance their current technology suite. The company aims to expand its market presence into new geographic regions, particularly targeting Europe and Asia by 2025. The recent funding will facilitate the development of these new products and support their entry into these strategic markets, bolstering their efforts in meeting the growing demand for efficient drug discovery solutions.